LANGHORNE, Pa., June 15, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO, will participate in a virtual fireside chat with Naz Rahman, CFA, Vice President, Senior Equity Research Analyst, at the Maxim Group Virtual Healthcare Conference being held on June 20th - 22nd.
Maxim Group Fireside Chat Details
Date: June 20, 2023
Presentation Time: 3:30 P.M. ET
Registration: HERE
The conference is being hosted by M-Vest, a division of Maxim. If you would like to schedule a meeting with NEXGEL, please contact your Maxim representative or send an email to NEXGEL@kcsa.com.
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com
Media Contacts:
Kelly Knobeck
Director of Consumer Products
info@nexgel.com
| Last Trade: | US$2.59 |
| Daily Change: | 0.03 1.17 |
| Daily Volume: | 13,467 |
| Market Cap: | US$17.590M |
November 13, 2024 November 11, 2024 October 10, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
